VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. (Q51622508)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Carlo-Federico Zambon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Roberto Padrini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Daniela Basso

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Stefania Schiavon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Paola Fogar

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Alessandra Nisi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Anna Chiara Frigo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Stefania Moz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Michela Pelloso

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Mario Plebani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

15-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21174619%20AND%20SRC:MED&resulttype=core&format=json

Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Clinically significant pharmacokinetic interactions between dietary caffeine and medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Genetic and clinical predictors of warfarin dose requirements in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162

Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.162